Previous 10 | Next 10 |
TEL AVIV, Israel , March 12, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator, Aramchol, an oral therapy for the treatment of non...
TEL AVIV, Israel , March 6, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment...
Author’s note: I'm very grateful to President and CEO Allen Baharaff, Dr. Liat Hayardeny and management for the call interview. Investment Thesis Galmed ( GLMD ) is a small market cap ($177M) Israeli clinical stage biopharma focused on the clinical development of its lead invest...
Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i...
Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce...
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...
Galmed Pharmaceuticals Ltd (GLMD) Q3 2018 Earnings Conference Call November 5, 2018 08:30 AM ET Executives Paul Arndt - Managing Director, LifeSci Advisors Allen Baharaff - Co-Founder, Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scien...
Galmed ( GLMD ) Q3 results: Revenues: $1.5M. More news on: Galmed Pharmaceuticals Ltd., Healthcare stocks news, Earnings news and commentary, , Read more ...
Galmed (NASDAQ: GLMD ): Q3 GAAP EPS of -$0.05 beats by $0.12 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Nov. 5, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nona...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for...
Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. A...